Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

IMAB362

 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

ClaudiximabMonoclonal Antibodies

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Zolbetuximab combined with EOX as first-line therapy in advanced CLDN18.2+ gastric (G) and gastroesophageal junction (GEJ) adenocarcinoma: Updated results from the FAST trial.
16Background: Physiologically, the tight junction protein CLDN18.2 is present only in the gastric mucosa. Upon malignant… Expand
Is this relevant?
2018
2018
A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer.
INTRODUCTION IMAB362 (Zolbetuximab) is a chimeric monoclonal antibody that binds to Claudin-18.2, a target antigen specific to… Expand
Is this relevant?
2016
2016
FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line…
LBA4001Background: Claudin18.2 (CLDN18.2) is a tight junction protein expressed by several cancers including gastric and GEJ… Expand
Is this relevant?
Review
2016
Review
2016
Advances in Systemic Therapy for Metastatic or Advanced Gastric Cancer.
In recent years, various new agents have been investigated for the treatment of advanced gastric cancer (AGC). The anti-HER2… Expand
  • table 1
  • table 2
Is this relevant?
2016
2016
Final results of the FAST study, an international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18.2 antibody IMAB362 as…
 
Is this relevant?
2015
2015
IMAB362 plus zoledronic acid (ZA) and interleukin-2 (IL-2) in patients (pts) with advanced gastroesophageal cancer (GEC): Clinical activity and safety data from the PILOT phase I trial.
e15079 Background: IMAB362 is the first-in-class monoclonal antibody against the tight junction molecule claudin 18.2 (CLDN18.2… Expand
Is this relevant?
2014
2014
Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms.
The majority of pancreatic neoplasms are characterized by a generally lethal progress within a short period of time after primary… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2014
2014
636PEFFICACY AND SAFETY OF MULTIPLE DOSES OF IMAB362 IN PATIENTS WITH ADVANCED GASTRO-ESOPHAGEAL CANCER: RESULTS OF A PHASE II STUDY.
ABSTRACT Aim: IMAB362 is a monoclonal antibody specifically targeting claudin 18 isoform 2 (CLDN18.2), which is expressed on… Expand
Is this relevant?
2014
2014
Abstract 2903: IMAB362, a novel first-in-class monoclonal antibody for treatment of pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC), the most frequent subtype (>80%) of pancreatic cancer (PC) is characterized by a… Expand
Is this relevant?
2013
2013
Safety, tolerability, and efficacy of the first-in-class antibody IMAB362 targeting claudin 18.2 in patients with metastatic gastroesophageal adenocarcinomas.
4080 Background: IMAB362 is a monoclonal antibody targeting isoform 2 of the tight junction component claudin 18 (CLDN18.2), a… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE